疑难病杂志
疑難病雜誌
의난병잡지
Chinese Journal of Difficult and Complicated Cases
2015年
10期
1074-1077
,共4页
养正消积胶囊%原发性肝癌%Meta分析%系统评价%随机对照试验
養正消積膠囊%原髮性肝癌%Meta分析%繫統評價%隨機對照試驗
양정소적효낭%원발성간암%Meta분석%계통평개%수궤대조시험
Yangzhengxiaoji capsule%Primary hepatocellular carcinoma%Meta-analysis%System evaluation%Ran-domized controlled trials
目的：系统评价养正消积胶囊配合介入化疗或放疗治疗原发性肝癌的临床疗效及安全性。方法计算机检索PubMed、EM-base、中国知网、万方数据、中国博士学位论文全文数据库、中国优秀硕士学位论文全文数据，全面收集养正消积胶囊治疗原发性肝癌的所有随机对照试验。采用RevMan 5°．3软件进行Meta 分析。结果共纳入8个文献，共1868例患者。 Meta分析结果显示：试验组与对照组相比，其实体肿瘤近期疗效有效率（OR＝1．36，95％CI 1．12～1．65， P ＝0．002）、生活质量（OR＝1．96，95％CI 1．52～2．54， P ＜0．01）及体质量升高率（OR＝1．97，95％CI 1．45～2．66， P ＜0．01）的差异均有统计学意义；其血白细胞下降（OR＝0．35，95％CI 0．25～0．50， P ＜0．01）、血小板下降（OR＝0．39，95％CI 0．28～0．54， P ＜0．01）及恶心呕吐发生率（OR＝0．30，95％CI 0．21～0．41， P ＜0．01）的差异均有统计学意义。结论养正消积胶囊配合介入化疗或放疗治疗原发性肝癌，能缩小肿瘤，改善生活质量、提供体质量，减轻放化疗的不良反应。
目的：繫統評價養正消積膠囊配閤介入化療或放療治療原髮性肝癌的臨床療效及安全性。方法計算機檢索PubMed、EM-base、中國知網、萬方數據、中國博士學位論文全文數據庫、中國優秀碩士學位論文全文數據，全麵收集養正消積膠囊治療原髮性肝癌的所有隨機對照試驗。採用RevMan 5°．3軟件進行Meta 分析。結果共納入8箇文獻，共1868例患者。 Meta分析結果顯示：試驗組與對照組相比，其實體腫瘤近期療效有效率（OR＝1．36，95％CI 1．12～1．65， P ＝0．002）、生活質量（OR＝1．96，95％CI 1．52～2．54， P ＜0．01）及體質量升高率（OR＝1．97，95％CI 1．45～2．66， P ＜0．01）的差異均有統計學意義；其血白細胞下降（OR＝0．35，95％CI 0．25～0．50， P ＜0．01）、血小闆下降（OR＝0．39，95％CI 0．28～0．54， P ＜0．01）及噁心嘔吐髮生率（OR＝0．30，95％CI 0．21～0．41， P ＜0．01）的差異均有統計學意義。結論養正消積膠囊配閤介入化療或放療治療原髮性肝癌，能縮小腫瘤，改善生活質量、提供體質量，減輕放化療的不良反應。
목적：계통평개양정소적효낭배합개입화료혹방료치료원발성간암적림상료효급안전성。방법계산궤검색PubMed、EM-base、중국지망、만방수거、중국박사학위논문전문수거고、중국우수석사학위논문전문수거，전면수집양정소적효낭치료원발성간암적소유수궤대조시험。채용RevMan 5°．3연건진행Meta 분석。결과공납입8개문헌，공1868례환자。 Meta분석결과현시：시험조여대조조상비，기실체종류근기료효유효솔（OR＝1．36，95％CI 1．12～1．65， P ＝0．002）、생활질량（OR＝1．96，95％CI 1．52～2．54， P ＜0．01）급체질량승고솔（OR＝1．97，95％CI 1．45～2．66， P ＜0．01）적차이균유통계학의의；기혈백세포하강（OR＝0．35，95％CI 0．25～0．50， P ＜0．01）、혈소판하강（OR＝0．39，95％CI 0．28～0．54， P ＜0．01）급악심구토발생솔（OR＝0．30，95％CI 0．21～0．41， P ＜0．01）적차이균유통계학의의。결론양정소적효낭배합개입화료혹방료치료원발성간암，능축소종류，개선생활질량、제공체질량，감경방화료적불량반응。
Objective To systemic evaluate the clinical efficacy and safety of Yangzhengxiaoji capsule combined with interventional chemotherapy or radiotherapy in the treatment of primary liver cancer .Methods Computer retrieval PubMed , EM and base, CNKI, Wanfang Data, Chinese doctoral dissertations full text database , China outstanding master's Degree Dis-sertation Full-text data, comprehensive collected all randomized controlled trials of Yangzhengxiaoji capsule in the treatment of primary hepatocellular carcinoma (HCC).Meta-analysis was performed using RevMan 5.3 software.Results A total of 8 lit-eratures were included , and a total of 1 868 patients were included .Meta-analysis results showed:compared the experimental group and the control group , recent effect of treating solid tumor (OR=1.36, 95%CI 1.12-1.65, P =0.002), quality of life (OR=1.96, 95%CI 1.52-2.54, P <0.01) and body mass increased rate (OR=1.97, 95%CI 1.45-2.66, P <0.01) were significant different;the white blood cells decreased rate (OR=0.35, 95%CI 0.25-0.50, P <0.01), platelet decreased rate (OR=0.39, 95%CI 0.28-0.54, P <0.01) and nausea vomiting occurred rate (OR=0.30, 95%CI 0.21-0.41, P <0.01)’s differences were different statistical significance .Conclusion Yangzhengxiaoji capsule combined with interventional chemotherapy or radiotherapy in the treatment of primary hepatocellular carcinoma can decrease tumor size , im-prove life quality , raise the quality of donor and reduce the adverse effects of radiotherapy and chemotherapy .
